Savill Corrine 4

What Happened
Corrine Savill, Chief Business Officer of Cullinan Therapeutics (CGEM), received a derivative equity award covering 175,000 shares on 2026-02-18. The filing shows an acquisition at $0.00 (no cash paid at grant). This was an award grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-18; Filing date: 2026-02-19 (filed the next day).
• Reported consideration: $0.00 (derivative award).
• Number of shares/units granted: 175,000 (derivative).
• Vesting: The shares underlying the option vest over four years — 1/48th vest in equal monthly installments until the fourth anniversary of the grant date (footnote F1).
• Shares owned after the transaction: not disclosed in the provided filing.
• Transaction type/code: Award/Grant (A); derivative instrument (option or similar) per footnote.

Context
This is a standard equity incentive grant used to retain and motivate executives; because it’s an award (derivative) rather than an outright purchase, it doesn’t indicate an immediate cash investment by the insider. Vesting means the shares must generally be earned over time (typically requiring continued employment) before the insider can exercise or own them outright.